Drug interactions should be evaluated in patients.

Area of Science:

• Pharmacology and Drug Development
• Clinical Pharmacology

Background:

• Drug development traditionally involves healthy volunteers before patient studies.
• Current drug-drug interaction (DDI) study designs often lack clinical relevance.
• Extrapolation of pharmacokinetic and pharmacodynamic data from healthy volunteers to patients is not always reliable.

Purpose of the Study:

• To advocate for the inclusion of patients in drug-drug interaction studies.
• To emphasize the need for clinically relevant DDI study designs.
• To improve guidance for healthcare professionals on safe and effective dosing.

Main Methods:

• Review of current drug development and DDI study methodologies.
• Analysis of the limitations in extrapolating data from healthy volunteers to patient populations.
• Assessment of the clinical utility of existing DDI study designs.

Main Results:

• Significant limitations exist in applying healthy volunteer data to predict patient responses to drug-drug interactions.
• Current DDI study designs frequently do not reflect real-world clinical scenarios.
• A gap exists in providing actionable DDI information for individual patient care.

Conclusions:

• Drug-drug interaction studies must incorporate the intended patient population.
• Study designs should prioritize clinical relevance and direct applicability to patient care.
• Improved DDI data in patients is crucial for guiding safe and effective pharmacotherapy.